공고 • Jun 09
Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US Operations Compumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida. 공고 • Oct 30
Compumedics Limited Elects Mr. Christopher Barys as Director Compumedics Limited elected Mr. Christopher Barys as director. 공고 • Oct 15
Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 7,543,860
Price\Range: AUD 0.285
Discount Per Security: AUD 0.0171
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 05
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 275% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. 공고 • Oct 01
Compumedics Limited, Annual General Meeting, Oct 30, 2025 Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, Australia New Risk • Aug 28
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Market cap is less than US$100m (AU$54.7m market cap, or US$35.6m). Reported Earnings • Aug 28
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Mar 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$61.5m market cap, or US$38.7m). Reported Earnings • Mar 04
First half 2025 earnings released First half 2025 results: Revenue: AU$47.1m (up 78% from 1H 2024). Net loss: AU$2.23m (down AU$2.37m from profit in 1H 2024). 공고 • Dec 05
Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 8,269,231
Price\Range: AUD 0.26
Discount Per Security: AUD 0.0156
Transaction Features: Subsequent Direct Listing Reported Earnings • Oct 02
Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023) Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. 공고 • Oct 01
Compumedics Limited, Annual General Meeting, Oct 31, 2024 Compumedics Limited, Annual General Meeting, Oct 31, 2024. Location: 30-40 flockhart street, abbotsford victoria 3067 Australia Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023) Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. New Risk • Jul 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m). New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (AU$51.4m market cap, or US$34.2m). New Risk • Nov 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risk Market cap is less than US$100m (AU$34.5m market cap, or US$22.5m). Reported Earnings • Oct 01
Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022) Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. 공고 • Sep 28
Compumedics Limited, Annual General Meeting, Oct 31, 2023 Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report. Reported Earnings • Aug 31
Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022) Full year 2023 results: AU$0.004 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 14% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. 공고 • Jul 06
Compumedics Limited Provides Revenue Guidance for the Year 2023 Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million. 공고 • May 06
Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023 Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million. Reported Earnings • Mar 03
First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022) First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 01
Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021) Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. 공고 • Sep 29
Compumedics Limited, Annual General Meeting, Oct 27, 2022 Compumedics Limited, Annual General Meeting, Oct 27, 2022, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the company and the reports of the directors and the company's auditor for the year ended 30 June 2022; to consider the re-election of director; and to consider the adoption of remuneration report. Reported Earnings • Aug 19
Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021) Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings. 공고 • Aug 18
Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023 Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공고 • Mar 31
Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022 Compumedics Limited announced that Mr. Tucson Dunn, who was appointed a Director of the Company in May 2018, will retire as a Director of the Company, effective 31 March, 2022. Reported Earnings • Mar 03
First half 2022 earnings: EPS and revenues miss analyst expectations First half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Reported Earnings • Oct 01
Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance. Reported Earnings • Aug 27
Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance. Is New 90 Day High Low • Mar 09
New 90-day low: AU$0.41 The company is down 16% from its price of AU$0.49 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period. Reported Earnings • Feb 25
First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020) The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$18.0m (down 1.4% from 1H 2020). Net income: AU$1.32m (up AU$1.16m from 1H 2020). Profit margin: 7.3% (up from 0.9% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 79% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Price Target Changed • Dec 01
Price target lowered to AU$1.00 Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year. 공고 • Sep 07
Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021 Compumedics Limited announced that the ongoing and uncertain impacts of the COVID-19 Pandemic on key markets around the world make it very difficult to forecast the Company's expected results, for any given future period. As such, the Company remains unable to provide guidance at this time for the fiscal year 2021. 공고 • Jul 17
Compumedics Limited Announces That Sales Forecasts Will Remain Problematic Due to COVID-19 Pandemic Compumedics Limited announced that initial sales pipelines for 2021 consistent with same time last year, with good new sales orders in the first weeks of 2021. Sales forecasts will remain problematic due to COVID-19 pandemic.